Review



mouse anti ido1  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Proteintech mouse anti ido1
    Mouse Anti Ido1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 135 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+ido1/10__1016_slash_j__cej__2026__172758-70-11-30?v=Proteintech
    Average 96 stars, based on 135 article reviews
    mouse anti ido1 - by Bioz Stars, 2026-07
    96/100 stars

    Images



    Similar Products

    93
    MedChemExpress mouse ido1 protein
    The expression of the endothelial NAD + de novo synthesis enzyme <t>IDO1</t> is reduced after lower limb ischemia in aged mice. (A) Scheme depicting the experiment for RNA-seq and NAD + -target metabolomics of young and aged mice following HLI. (B) Diagram showing the pathway of NAD + synthesis and consuming. (C) Volcano plot of transcriptional alterations in hindlimb muscle ECs 7 days after HLI. (D) RNA-seq analysis of NAD + metabolism related enzymes in hindlimb muscle ECs 7 days after HLI. Young group was set as 1. Two-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001. (E) Heatmap of the NAD + related metabolites in hindlimb muscle ECs 7 days after HLI. Young group was set as 1. Two-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (F) Western blot analysis and quantification of IDO1 in hindlimb muscle ECs 7 days after HLI. Young group was set as 1. Unpaired two-tail t -test, n = 3 per group, data are mean ± SEM, ∗∗∗ P < 0.001. (G) Violin plots of log-transformed gene expression of Ido1 in cell populations of hindlimb muscle from young and aged mice following HLI. (H) Violin plots of log-transformed gene expression of IDO1 in cell populations of lower-limb muscle of PAD patients.
    Mouse Ido1 Protein, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+ido1/pmc12158617-63-21-49?v=MedChemExpress
    Average 93 stars, based on 1 article reviews
    mouse ido1 protein - by Bioz Stars, 2026-07
    93/100 stars
      Buy from Supplier

    94
    OriGene 2 3 dioxygenase 1 ido1
    The expression of the endothelial NAD + de novo synthesis enzyme <t>IDO1</t> is reduced after lower limb ischemia in aged mice. (A) Scheme depicting the experiment for RNA-seq and NAD + -target metabolomics of young and aged mice following HLI. (B) Diagram showing the pathway of NAD + synthesis and consuming. (C) Volcano plot of transcriptional alterations in hindlimb muscle ECs 7 days after HLI. (D) RNA-seq analysis of NAD + metabolism related enzymes in hindlimb muscle ECs 7 days after HLI. Young group was set as 1. Two-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001. (E) Heatmap of the NAD + related metabolites in hindlimb muscle ECs 7 days after HLI. Young group was set as 1. Two-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (F) Western blot analysis and quantification of IDO1 in hindlimb muscle ECs 7 days after HLI. Young group was set as 1. Unpaired two-tail t -test, n = 3 per group, data are mean ± SEM, ∗∗∗ P < 0.001. (G) Violin plots of log-transformed gene expression of Ido1 in cell populations of hindlimb muscle from young and aged mice following HLI. (H) Violin plots of log-transformed gene expression of IDO1 in cell populations of lower-limb muscle of PAD patients.
    2 3 Dioxygenase 1 Ido1, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+ido1/10__1097_slash_js9__0000000000004835-89-19-22?v=OriGene
    Average 94 stars, based on 1 article reviews
    2 3 dioxygenase 1 ido1 - by Bioz Stars, 2026-07
    94/100 stars
      Buy from Supplier

    96
    Proteintech mouse anti ido1
    The expression of the endothelial NAD + de novo synthesis enzyme <t>IDO1</t> is reduced after lower limb ischemia in aged mice. (A) Scheme depicting the experiment for RNA-seq and NAD + -target metabolomics of young and aged mice following HLI. (B) Diagram showing the pathway of NAD + synthesis and consuming. (C) Volcano plot of transcriptional alterations in hindlimb muscle ECs 7 days after HLI. (D) RNA-seq analysis of NAD + metabolism related enzymes in hindlimb muscle ECs 7 days after HLI. Young group was set as 1. Two-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001. (E) Heatmap of the NAD + related metabolites in hindlimb muscle ECs 7 days after HLI. Young group was set as 1. Two-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (F) Western blot analysis and quantification of IDO1 in hindlimb muscle ECs 7 days after HLI. Young group was set as 1. Unpaired two-tail t -test, n = 3 per group, data are mean ± SEM, ∗∗∗ P < 0.001. (G) Violin plots of log-transformed gene expression of Ido1 in cell populations of hindlimb muscle from young and aged mice following HLI. (H) Violin plots of log-transformed gene expression of IDO1 in cell populations of lower-limb muscle of PAD patients.
    Mouse Anti Ido1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+ido1/10__1016_slash_j__cej__2026__172758-70-11-30?v=Proteintech
    Average 96 stars, based on 1 article reviews
    mouse anti ido1 - by Bioz Stars, 2026-07
    96/100 stars
      Buy from Supplier

    96
    Proteintech rabbit anti mouse ido primary antibody
    The expression of the endothelial NAD + de novo synthesis enzyme <t>IDO1</t> is reduced after lower limb ischemia in aged mice. (A) Scheme depicting the experiment for RNA-seq and NAD + -target metabolomics of young and aged mice following HLI. (B) Diagram showing the pathway of NAD + synthesis and consuming. (C) Volcano plot of transcriptional alterations in hindlimb muscle ECs 7 days after HLI. (D) RNA-seq analysis of NAD + metabolism related enzymes in hindlimb muscle ECs 7 days after HLI. Young group was set as 1. Two-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001. (E) Heatmap of the NAD + related metabolites in hindlimb muscle ECs 7 days after HLI. Young group was set as 1. Two-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (F) Western blot analysis and quantification of IDO1 in hindlimb muscle ECs 7 days after HLI. Young group was set as 1. Unpaired two-tail t -test, n = 3 per group, data are mean ± SEM, ∗∗∗ P < 0.001. (G) Violin plots of log-transformed gene expression of Ido1 in cell populations of hindlimb muscle from young and aged mice following HLI. (H) Violin plots of log-transformed gene expression of IDO1 in cell populations of lower-limb muscle of PAD patients.
    Rabbit Anti Mouse Ido Primary Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+ido1/pmc12468408-88-18-24?v=Proteintech
    Average 96 stars, based on 1 article reviews
    rabbit anti mouse ido primary antibody - by Bioz Stars, 2026-07
    96/100 stars
      Buy from Supplier

    93
    OriGene anti human ido1
    The expression of the endothelial NAD + de novo synthesis enzyme <t>IDO1</t> is reduced after lower limb ischemia in aged mice. (A) Scheme depicting the experiment for RNA-seq and NAD + -target metabolomics of young and aged mice following HLI. (B) Diagram showing the pathway of NAD + synthesis and consuming. (C) Volcano plot of transcriptional alterations in hindlimb muscle ECs 7 days after HLI. (D) RNA-seq analysis of NAD + metabolism related enzymes in hindlimb muscle ECs 7 days after HLI. Young group was set as 1. Two-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001. (E) Heatmap of the NAD + related metabolites in hindlimb muscle ECs 7 days after HLI. Young group was set as 1. Two-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (F) Western blot analysis and quantification of IDO1 in hindlimb muscle ECs 7 days after HLI. Young group was set as 1. Unpaired two-tail t -test, n = 3 per group, data are mean ± SEM, ∗∗∗ P < 0.001. (G) Violin plots of log-transformed gene expression of Ido1 in cell populations of hindlimb muscle from young and aged mice following HLI. (H) Violin plots of log-transformed gene expression of IDO1 in cell populations of lower-limb muscle of PAD patients.
    Anti Human Ido1, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+ido1/pm39899472-90-64-69?v=OriGene
    Average 93 stars, based on 1 article reviews
    anti human ido1 - by Bioz Stars, 2026-07
    93/100 stars
      Buy from Supplier

    96
    Proteintech mouse anti ido
    FIGURE 2 | UB treatment ameliorates depression-like behaviors and neuroinflammation and abnormal expression of SIRT1 <t>and</t> <t>FOXO1</t> in the hippocampus of LPS-exposed mice. (A) Scheme of the experimental procedure. (B) SPT, FST, and locomotor tests. (C) Relative mRNA levels of TNF-ɑ, IL-1ɑ, IL-1β, IL-6, and <t>IDO</t> in the hippocampus. mRNA levels of M1 type markers iNOS and CD86 (D), and M2 type markers ARG1 and CD206 (E) in the hippocampus. (F and G) Western blot was performed to evaluate the effect of UB on the protein levels of Iba1, IDO, SIRT1, and FOXO1 in the hippocampus. n = 6–7 per group. #p < 0.05, ##p < 0.01, ###p < 0.001 versus the Vehicle + Vehicle group or LPS + Vehicle group.
    Mouse Anti Ido, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+ido1/pm40237232-94-98-101?v=Proteintech
    Average 96 stars, based on 1 article reviews
    mouse anti ido - by Bioz Stars, 2026-07
    96/100 stars
      Buy from Supplier

    93
    OriGene ido 1 umab126 origene technologies
    FIGURE 2 | UB treatment ameliorates depression-like behaviors and neuroinflammation and abnormal expression of SIRT1 <t>and</t> <t>FOXO1</t> in the hippocampus of LPS-exposed mice. (A) Scheme of the experimental procedure. (B) SPT, FST, and locomotor tests. (C) Relative mRNA levels of TNF-ɑ, IL-1ɑ, IL-1β, IL-6, and <t>IDO</t> in the hippocampus. mRNA levels of M1 type markers iNOS and CD86 (D), and M2 type markers ARG1 and CD206 (E) in the hippocampus. (F and G) Western blot was performed to evaluate the effect of UB on the protein levels of Iba1, IDO, SIRT1, and FOXO1 in the hippocampus. n = 6–7 per group. #p < 0.05, ##p < 0.01, ###p < 0.001 versus the Vehicle + Vehicle group or LPS + Vehicle group.
    Ido 1 Umab126 Origene Technologies, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+ido1/pmc12044655__CAS___116___1464___s001-13-46-48?v=OriGene
    Average 93 stars, based on 1 article reviews
    ido 1 umab126 origene technologies - by Bioz Stars, 2026-07
    93/100 stars
      Buy from Supplier

    96
    Proteintech mouse
    FIGURE 2 | UB treatment ameliorates depression-like behaviors and neuroinflammation and abnormal expression of SIRT1 <t>and</t> <t>FOXO1</t> in the hippocampus of LPS-exposed mice. (A) Scheme of the experimental procedure. (B) SPT, FST, and locomotor tests. (C) Relative mRNA levels of TNF-ɑ, IL-1ɑ, IL-1β, IL-6, and <t>IDO</t> in the hippocampus. mRNA levels of M1 type markers iNOS and CD86 (D), and M2 type markers ARG1 and CD206 (E) in the hippocampus. (F and G) Western blot was performed to evaluate the effect of UB on the protein levels of Iba1, IDO, SIRT1, and FOXO1 in the hippocampus. n = 6–7 per group. #p < 0.05, ##p < 0.01, ###p < 0.001 versus the Vehicle + Vehicle group or LPS + Vehicle group.
    Mouse, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+ido1/10__1002_slash_imo2__34-227-16-21?v=Proteintech
    Average 96 stars, based on 1 article reviews
    mouse - by Bioz Stars, 2026-07
    96/100 stars
      Buy from Supplier

    Image Search Results


    The expression of the endothelial NAD + de novo synthesis enzyme IDO1 is reduced after lower limb ischemia in aged mice. (A) Scheme depicting the experiment for RNA-seq and NAD + -target metabolomics of young and aged mice following HLI. (B) Diagram showing the pathway of NAD + synthesis and consuming. (C) Volcano plot of transcriptional alterations in hindlimb muscle ECs 7 days after HLI. (D) RNA-seq analysis of NAD + metabolism related enzymes in hindlimb muscle ECs 7 days after HLI. Young group was set as 1. Two-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001. (E) Heatmap of the NAD + related metabolites in hindlimb muscle ECs 7 days after HLI. Young group was set as 1. Two-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (F) Western blot analysis and quantification of IDO1 in hindlimb muscle ECs 7 days after HLI. Young group was set as 1. Unpaired two-tail t -test, n = 3 per group, data are mean ± SEM, ∗∗∗ P < 0.001. (G) Violin plots of log-transformed gene expression of Ido1 in cell populations of hindlimb muscle from young and aged mice following HLI. (H) Violin plots of log-transformed gene expression of IDO1 in cell populations of lower-limb muscle of PAD patients.

    Journal: Redox Biology

    Article Title: IDO1 improves postischemic neovascularization in aged mice by boosting endothelial NAD + de novo synthesis and curbing endothelial senescence

    doi: 10.1016/j.redox.2025.103695

    Figure Lengend Snippet: The expression of the endothelial NAD + de novo synthesis enzyme IDO1 is reduced after lower limb ischemia in aged mice. (A) Scheme depicting the experiment for RNA-seq and NAD + -target metabolomics of young and aged mice following HLI. (B) Diagram showing the pathway of NAD + synthesis and consuming. (C) Volcano plot of transcriptional alterations in hindlimb muscle ECs 7 days after HLI. (D) RNA-seq analysis of NAD + metabolism related enzymes in hindlimb muscle ECs 7 days after HLI. Young group was set as 1. Two-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001. (E) Heatmap of the NAD + related metabolites in hindlimb muscle ECs 7 days after HLI. Young group was set as 1. Two-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (F) Western blot analysis and quantification of IDO1 in hindlimb muscle ECs 7 days after HLI. Young group was set as 1. Unpaired two-tail t -test, n = 3 per group, data are mean ± SEM, ∗∗∗ P < 0.001. (G) Violin plots of log-transformed gene expression of Ido1 in cell populations of hindlimb muscle from young and aged mice following HLI. (H) Violin plots of log-transformed gene expression of IDO1 in cell populations of lower-limb muscle of PAD patients.

    Article Snippet: Mouse IL-17A protein (Catalog #HY- P70753 ), mouse IL-17F protein (Catalog #HY- P72584 ), mouse IL-17A/F protein (Catalog #HY- P77707 ), mouse IDO1 protein (Catalog #HY- P72616 ), IgG (Catalog #HY-P99002), brodalumab (Catalog #HY-P9925, an anti-interleukin-17-receptor IgG2 monoclonal antibody), and 666–15 (Catalog #HY-101120, CREB phosphorylation inhibitor) were purchased from Med-ChemExpress.

    Techniques: Expressing, RNA Sequencing, Comparison, Western Blot, Transformation Assay, Gene Expression

    Ido1 deficiency leads to ECs senescence and impairs neovascularization in the ischemic hindlimb muscle of young mice. (A) Design showing the experiment for ECs senescence and vasculogenic phenotypes in Ido1 −/− mice. (B) Mass spectrometry analysis of NAD + related metabolites in hindlimb muscle ECs 7 days after HLI. WT group was set as 1. Two-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001, ns: not significant. (C) Western blot analysis and quantification of P16 in hindlimb muscle ECs 7 days after HLI. WT group was set as 1. Unpaired two-tail t -test, n = 3 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001. (D–F) RT-qPCR quantification of p16 (D), p21 (E) and Lmnb1 (F) in hindlimb muscle ECs 7 days after HLI. WT group was set as 1. Unpaired two-tail t -test, n = 3 per group, data are mean ± SEM, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001. (G, H) ROS levels (G) and NO levels (H) quantification in hindlimb muscle ECs 7 days after HLI. Data of WT group in G was set as 1. Unpaired two-tail t -test, n = 3 per group, data are mean ± SEM, ∗ P < 0.05, ∗∗∗∗ P < 0.0001. (I) Immunofluorescence staining for CD31, α-SMA and KI67 in ischemic adductor muscles 7 days after HLI is shown. Scale bar, 200 μm. (J) Quantification of the percent of KI67 + arterial ECs in total arterial ECs in muscle. Unpaired two-tail t -test, n = 6 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001. (K) Immunofluorescence staining for CD31 and KI67 in ischemic gastrocnemius muscles 7 days after HLI is shown. Scale bar, 200 μm. (L) Quantification of the percent of KI67 + CD31 + cells in total capillary ECs in muscle. Unpaired two-tail t -test, n = 6 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001. (M) Immunofluorescence staining for CD31, α-SMA and γ-H2AX in ischemic adductor muscles 7 days after HLI is shown. Scale bar, 100 μm. (N) Quantification of the percent of γ-H2AX + arterial ECs in total arterial ECs in muscle. Unpaired two-tail t -test, n = 6 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001. (O) Immunofluorescence staining for CD31 and γ-H2AX in ischemic gastrocnemius muscles 7 days after HLI is shown. Scale bar, 100 μm. (P) Quantification of the percent of γ-H2AX + CD31 + cells in total capillary ECs in muscle. Unpaired two-tail t -test, n = 6 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001. (Q and R) Representative laser Doppler images (Q) of hindlimbs of mice and quantification (R) of relative perfusion recovery as the blood flow ratio of the left limb to that of the right limb in WT and Ido1 −/− mice before and after HLI at the indicated time points. The areas under the curves of relative perfusion are shown, Two-way ANOVA with Tukey multiple comparison test, n = 6 per group, data are mean ± SEM, ∗∗ P < 0.01, ∗∗∗∗ P < 0.0001. (S) Representative micro-CT images of ischemic hindlimbs 21 days after HLI. Scale bar, 3 mm. (T) Quantification of micro-CT analysis of arterial vasculature in ischemic hindlimbs. Two-way ANOVA with Tukey multiple comparison test, n = 6 per group, data are mean ± SEM, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (U) Representative whole-mounted images of ischemic gracilis 21 days after HLI. (V) Quantification of the diameter of pre-existed collateral arteries (6 points per artery). Unpaired two-tail t -test, n = 6 per group, data are mean ± SEM, ∗∗∗ P < 0.001. (W) Immunofluorescence staining for CD31 in ischemic gastrocnemius muscles 21 days after HLI is shown. Scale bar, 200 μm. (X) Quantification of the CD31-positive area in muscle. Unpaired two-tail t -test, n = 6 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001.

    Journal: Redox Biology

    Article Title: IDO1 improves postischemic neovascularization in aged mice by boosting endothelial NAD + de novo synthesis and curbing endothelial senescence

    doi: 10.1016/j.redox.2025.103695

    Figure Lengend Snippet: Ido1 deficiency leads to ECs senescence and impairs neovascularization in the ischemic hindlimb muscle of young mice. (A) Design showing the experiment for ECs senescence and vasculogenic phenotypes in Ido1 −/− mice. (B) Mass spectrometry analysis of NAD + related metabolites in hindlimb muscle ECs 7 days after HLI. WT group was set as 1. Two-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001, ns: not significant. (C) Western blot analysis and quantification of P16 in hindlimb muscle ECs 7 days after HLI. WT group was set as 1. Unpaired two-tail t -test, n = 3 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001. (D–F) RT-qPCR quantification of p16 (D), p21 (E) and Lmnb1 (F) in hindlimb muscle ECs 7 days after HLI. WT group was set as 1. Unpaired two-tail t -test, n = 3 per group, data are mean ± SEM, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001. (G, H) ROS levels (G) and NO levels (H) quantification in hindlimb muscle ECs 7 days after HLI. Data of WT group in G was set as 1. Unpaired two-tail t -test, n = 3 per group, data are mean ± SEM, ∗ P < 0.05, ∗∗∗∗ P < 0.0001. (I) Immunofluorescence staining for CD31, α-SMA and KI67 in ischemic adductor muscles 7 days after HLI is shown. Scale bar, 200 μm. (J) Quantification of the percent of KI67 + arterial ECs in total arterial ECs in muscle. Unpaired two-tail t -test, n = 6 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001. (K) Immunofluorescence staining for CD31 and KI67 in ischemic gastrocnemius muscles 7 days after HLI is shown. Scale bar, 200 μm. (L) Quantification of the percent of KI67 + CD31 + cells in total capillary ECs in muscle. Unpaired two-tail t -test, n = 6 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001. (M) Immunofluorescence staining for CD31, α-SMA and γ-H2AX in ischemic adductor muscles 7 days after HLI is shown. Scale bar, 100 μm. (N) Quantification of the percent of γ-H2AX + arterial ECs in total arterial ECs in muscle. Unpaired two-tail t -test, n = 6 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001. (O) Immunofluorescence staining for CD31 and γ-H2AX in ischemic gastrocnemius muscles 7 days after HLI is shown. Scale bar, 100 μm. (P) Quantification of the percent of γ-H2AX + CD31 + cells in total capillary ECs in muscle. Unpaired two-tail t -test, n = 6 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001. (Q and R) Representative laser Doppler images (Q) of hindlimbs of mice and quantification (R) of relative perfusion recovery as the blood flow ratio of the left limb to that of the right limb in WT and Ido1 −/− mice before and after HLI at the indicated time points. The areas under the curves of relative perfusion are shown, Two-way ANOVA with Tukey multiple comparison test, n = 6 per group, data are mean ± SEM, ∗∗ P < 0.01, ∗∗∗∗ P < 0.0001. (S) Representative micro-CT images of ischemic hindlimbs 21 days after HLI. Scale bar, 3 mm. (T) Quantification of micro-CT analysis of arterial vasculature in ischemic hindlimbs. Two-way ANOVA with Tukey multiple comparison test, n = 6 per group, data are mean ± SEM, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (U) Representative whole-mounted images of ischemic gracilis 21 days after HLI. (V) Quantification of the diameter of pre-existed collateral arteries (6 points per artery). Unpaired two-tail t -test, n = 6 per group, data are mean ± SEM, ∗∗∗ P < 0.001. (W) Immunofluorescence staining for CD31 in ischemic gastrocnemius muscles 21 days after HLI is shown. Scale bar, 200 μm. (X) Quantification of the CD31-positive area in muscle. Unpaired two-tail t -test, n = 6 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001.

    Article Snippet: Mouse IL-17A protein (Catalog #HY- P70753 ), mouse IL-17F protein (Catalog #HY- P72584 ), mouse IL-17A/F protein (Catalog #HY- P77707 ), mouse IDO1 protein (Catalog #HY- P72616 ), IgG (Catalog #HY-P99002), brodalumab (Catalog #HY-P9925, an anti-interleukin-17-receptor IgG2 monoclonal antibody), and 666–15 (Catalog #HY-101120, CREB phosphorylation inhibitor) were purchased from Med-ChemExpress.

    Techniques: Mass Spectrometry, Comparison, Western Blot, Quantitative RT-PCR, Immunofluorescence, Staining, Muscles, Micro-CT

    IL-17A/F represses ECs Ido1 transactivation and NAD + biosynthesis, and facilitates ECs senescence in the ischemic hindlimb muscle of young mice. A) Schematic diagram for testing methods was indicated. (B) Bar plot of the most prominent categories by KEGG pathway (left) and GO analysis (right). (C) Western blot analysis and quantification of IDO1 in hindlimb muscle ECs 7 days after HLI. PBS group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗ P < 0.01, ∗∗∗ P < 0.001. (D) RT-qPCR quantification of Ido1 in hindlimb muscle ECs 7 days after HLI. PBS group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗ P < 0.05. (E) Western blot analysis and quantification of IDO1 and P16 in hindlimb muscle ECs 7 days after HLI. Con group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗ P < 0.01, ∗∗∗∗ P < 0.0001, ns: not significant. (F–I) RT-qPCR quantification of Ido1 (F), p16 (G) , p21 (H) and Lmnb1 (I) in hindlimb muscle ECs 7 days after HLI. Con group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (J–L) ROS (J), NAD + (K) and NO (L) levels quantification in in hindlimb muscle ECs 7 days after HLI. Data of Con group in J was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (M) Venn diagram of IDO1 transcriptional factors between mouse and human. (N) Western blot analysis and quantification of P-CREB and total-CREB in hindlimb muscle ECs 7 days after HLI. Young group was set as 1. Unpaired two-tail t -test, n = 3 per group, data are mean ± SEM, ∗∗∗ P < 0.001. (O, P) Western blot analysis and quantification of P-CREB, total-CREB (T-CREB) (O), IDO1(P) and P16 (P) in hindlimb muscle ECs 7 days after HLI. Con group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (Q–T) RT-qPCR quantification of Ido1 (Q), p16 (R) , p21 (S) and Lmnb1 (T) in hindlimb muscle ECs 7 days after HLI. Con group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ns: not significant. (U–W) ROS (U), NAD + (V) and NO (W) levels quantification in in hindlimb muscle ECs 7 days after HLI. Data of Con group in U was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant.

    Journal: Redox Biology

    Article Title: IDO1 improves postischemic neovascularization in aged mice by boosting endothelial NAD + de novo synthesis and curbing endothelial senescence

    doi: 10.1016/j.redox.2025.103695

    Figure Lengend Snippet: IL-17A/F represses ECs Ido1 transactivation and NAD + biosynthesis, and facilitates ECs senescence in the ischemic hindlimb muscle of young mice. A) Schematic diagram for testing methods was indicated. (B) Bar plot of the most prominent categories by KEGG pathway (left) and GO analysis (right). (C) Western blot analysis and quantification of IDO1 in hindlimb muscle ECs 7 days after HLI. PBS group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗ P < 0.01, ∗∗∗ P < 0.001. (D) RT-qPCR quantification of Ido1 in hindlimb muscle ECs 7 days after HLI. PBS group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗ P < 0.05. (E) Western blot analysis and quantification of IDO1 and P16 in hindlimb muscle ECs 7 days after HLI. Con group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗ P < 0.01, ∗∗∗∗ P < 0.0001, ns: not significant. (F–I) RT-qPCR quantification of Ido1 (F), p16 (G) , p21 (H) and Lmnb1 (I) in hindlimb muscle ECs 7 days after HLI. Con group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (J–L) ROS (J), NAD + (K) and NO (L) levels quantification in in hindlimb muscle ECs 7 days after HLI. Data of Con group in J was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (M) Venn diagram of IDO1 transcriptional factors between mouse and human. (N) Western blot analysis and quantification of P-CREB and total-CREB in hindlimb muscle ECs 7 days after HLI. Young group was set as 1. Unpaired two-tail t -test, n = 3 per group, data are mean ± SEM, ∗∗∗ P < 0.001. (O, P) Western blot analysis and quantification of P-CREB, total-CREB (T-CREB) (O), IDO1(P) and P16 (P) in hindlimb muscle ECs 7 days after HLI. Con group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (Q–T) RT-qPCR quantification of Ido1 (Q), p16 (R) , p21 (S) and Lmnb1 (T) in hindlimb muscle ECs 7 days after HLI. Con group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ns: not significant. (U–W) ROS (U), NAD + (V) and NO (W) levels quantification in in hindlimb muscle ECs 7 days after HLI. Data of Con group in U was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant.

    Article Snippet: Mouse IL-17A protein (Catalog #HY- P70753 ), mouse IL-17F protein (Catalog #HY- P72584 ), mouse IL-17A/F protein (Catalog #HY- P77707 ), mouse IDO1 protein (Catalog #HY- P72616 ), IgG (Catalog #HY-P99002), brodalumab (Catalog #HY-P9925, an anti-interleukin-17-receptor IgG2 monoclonal antibody), and 666–15 (Catalog #HY-101120, CREB phosphorylation inhibitor) were purchased from Med-ChemExpress.

    Techniques: Western Blot, Comparison, Quantitative RT-PCR

    IL-17A/F counteracts Endothelial Ido1 overexpression-induced neovascularization under conditions of lower limb ischemia. (A) Scheme showing the experiment for rescuing the IL-17A/F-treated young mice by endothelial Ido1 overexpression. (B and C) Representative laser Doppler images (B) of hindlimbs of mice and quantification (C) of relative perfusion recovery as the blood flow ratio of the left limb to that of the right limb in AAV-NC + PBS, AAV-NC + IL-17A/F, AAV- Ido1 + PBS and AAV- Ido1 + IL-17A/F mice before and after HLI at the indicated time points. The areas under the curves of relative perfusion are shown, Two-way ANOVA with Tukey multiple comparison test, n = 6 per group, data are mean ± SEM, ∗AAV-NC + IL-17A/F vs. AAV-NC + PBS; # AAV- Ido1 + IL-17A/F vs. AAV-NC+ IL-17A/F, #/ ∗ P < 0.05, ### P < 0.001, ∗∗∗∗/ #### P < 0.0001. (D) Representative micro-CT images of ischemic hindlimbs 21 days after HLI. Scale bar, 3 mm. (E) Quantification of micro-CT analysis of arterial vasculature in ischemic hindlimbs. Two-way ANOVA with Tukey multiple comparison test, n = 6 per group, data are mean ± SEM, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (F) Representative whole-mounted images of ischemic gracilis 21 days after HLI. (G) Quantification of the diameter of pre-existed collateral arteries (6 points per artery). One-way ANOVA with Tukey multiple comparison test, n = 6 per group, data are mean ± SEM, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001. (H) Immunofluorescence staining for CD31 in ischemic gastrocnemius muscles 21 days after HLI is shown. Scale bar, 200 μm. (I) Quantification of the CD31-positive area in muscle. One-way ANOVA with Tukey multiple comparison test, n = 6 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001.

    Journal: Redox Biology

    Article Title: IDO1 improves postischemic neovascularization in aged mice by boosting endothelial NAD + de novo synthesis and curbing endothelial senescence

    doi: 10.1016/j.redox.2025.103695

    Figure Lengend Snippet: IL-17A/F counteracts Endothelial Ido1 overexpression-induced neovascularization under conditions of lower limb ischemia. (A) Scheme showing the experiment for rescuing the IL-17A/F-treated young mice by endothelial Ido1 overexpression. (B and C) Representative laser Doppler images (B) of hindlimbs of mice and quantification (C) of relative perfusion recovery as the blood flow ratio of the left limb to that of the right limb in AAV-NC + PBS, AAV-NC + IL-17A/F, AAV- Ido1 + PBS and AAV- Ido1 + IL-17A/F mice before and after HLI at the indicated time points. The areas under the curves of relative perfusion are shown, Two-way ANOVA with Tukey multiple comparison test, n = 6 per group, data are mean ± SEM, ∗AAV-NC + IL-17A/F vs. AAV-NC + PBS; # AAV- Ido1 + IL-17A/F vs. AAV-NC+ IL-17A/F, #/ ∗ P < 0.05, ### P < 0.001, ∗∗∗∗/ #### P < 0.0001. (D) Representative micro-CT images of ischemic hindlimbs 21 days after HLI. Scale bar, 3 mm. (E) Quantification of micro-CT analysis of arterial vasculature in ischemic hindlimbs. Two-way ANOVA with Tukey multiple comparison test, n = 6 per group, data are mean ± SEM, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (F) Representative whole-mounted images of ischemic gracilis 21 days after HLI. (G) Quantification of the diameter of pre-existed collateral arteries (6 points per artery). One-way ANOVA with Tukey multiple comparison test, n = 6 per group, data are mean ± SEM, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001. (H) Immunofluorescence staining for CD31 in ischemic gastrocnemius muscles 21 days after HLI is shown. Scale bar, 200 μm. (I) Quantification of the CD31-positive area in muscle. One-way ANOVA with Tukey multiple comparison test, n = 6 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001.

    Article Snippet: Mouse IL-17A protein (Catalog #HY- P70753 ), mouse IL-17F protein (Catalog #HY- P72584 ), mouse IL-17A/F protein (Catalog #HY- P77707 ), mouse IDO1 protein (Catalog #HY- P72616 ), IgG (Catalog #HY-P99002), brodalumab (Catalog #HY-P9925, an anti-interleukin-17-receptor IgG2 monoclonal antibody), and 666–15 (Catalog #HY-101120, CREB phosphorylation inhibitor) were purchased from Med-ChemExpress.

    Techniques: Over Expression, Comparison, Micro-CT, Immunofluorescence, Staining, Muscles

    IDO1 protein alleviates ECs senescence, and boosts ECs migration, tube formation and proliferation in vitro . (A) Schematic diagram for HUVECs treated with H 2 O 2 for 24 h and incubated with or without IDO1 for 24 h. (B and C) Cell senescence was determined using SA-β-Gal staining, and the SA-β-Gal positive cells were quantified. Scale bar, 75 μm. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001, ns: not significant. (D) P16 levels were measured using western blot analysis, and the mean gray value was quantified. Con group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001, ns: not significant. (E–G) P16 (E) , P21 (F) and LMNB1 (G) levels were analyzed using RT-qPCR analysis. Con group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗∗ P < 0.001, ns: not significant. (H–J) ROS (H), NAD + (I) and NO (J) levels were quantified. Data of Con group in H was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (K and L) Cell migration was evaluated using a transwell assay, and the migrated cells were quantified. Scale bar, 75 μm. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001, ns: not significant. (M and N) Endothelial tube formation in Matrigel was assessed, and the total branch length was quantified. Scale bar, 75 μm. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗ P < 0.05, ns: not significant. (O and P) Cell proliferation was analyzed using EdU staining, and the EdU positive cells were quantified. Scale bar, 75 μm. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001, ns: not significant.

    Journal: Redox Biology

    Article Title: IDO1 improves postischemic neovascularization in aged mice by boosting endothelial NAD + de novo synthesis and curbing endothelial senescence

    doi: 10.1016/j.redox.2025.103695

    Figure Lengend Snippet: IDO1 protein alleviates ECs senescence, and boosts ECs migration, tube formation and proliferation in vitro . (A) Schematic diagram for HUVECs treated with H 2 O 2 for 24 h and incubated with or without IDO1 for 24 h. (B and C) Cell senescence was determined using SA-β-Gal staining, and the SA-β-Gal positive cells were quantified. Scale bar, 75 μm. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001, ns: not significant. (D) P16 levels were measured using western blot analysis, and the mean gray value was quantified. Con group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001, ns: not significant. (E–G) P16 (E) , P21 (F) and LMNB1 (G) levels were analyzed using RT-qPCR analysis. Con group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗∗ P < 0.001, ns: not significant. (H–J) ROS (H), NAD + (I) and NO (J) levels were quantified. Data of Con group in H was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (K and L) Cell migration was evaluated using a transwell assay, and the migrated cells were quantified. Scale bar, 75 μm. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001, ns: not significant. (M and N) Endothelial tube formation in Matrigel was assessed, and the total branch length was quantified. Scale bar, 75 μm. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗ P < 0.05, ns: not significant. (O and P) Cell proliferation was analyzed using EdU staining, and the EdU positive cells were quantified. Scale bar, 75 μm. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001, ns: not significant.

    Article Snippet: Mouse IL-17A protein (Catalog #HY- P70753 ), mouse IL-17F protein (Catalog #HY- P72584 ), mouse IL-17A/F protein (Catalog #HY- P77707 ), mouse IDO1 protein (Catalog #HY- P72616 ), IgG (Catalog #HY-P99002), brodalumab (Catalog #HY-P9925, an anti-interleukin-17-receptor IgG2 monoclonal antibody), and 666–15 (Catalog #HY-101120, CREB phosphorylation inhibitor) were purchased from Med-ChemExpress.

    Techniques: Migration, In Vitro, Incubation, Staining, Comparison, Western Blot, Quantitative RT-PCR, Transwell Assay

    IDO1 protein enhances the neovascularization in aged mice following lower limb ischemia. (A) Scheme illustrating the experiment of aged mice administrated with IDO1 protein. (B) Mass spectrometry analysis of NAD + related metabolites in hindlimb muscle ECs 7 days after HLI. Aged + PBS group was set as 1. Two-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗ P < 0.05, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (C) Western blot analysis and quantification of P16 in hindlimb muscle ECs 7 days after HLI. Aged + PBS group was set as 1. Unpaired two-tail t -test, n = 3 per group, data are mean ± SEM, ∗∗∗ P < 0.001. (D–F) RT-qPCR quantification of p16 (D), p21 (E), Lmnb1 (F) in hindlimb muscle ECs 7 days after HLI. Aged + PBS group was set as 1. Unpaired two-tail t -test, n = 3 per group, data are mean ± SEM, ∗ P < 0.05, ∗∗ P < 0.01. (G and H) ROS (G) and NO (H) levels quantification in hindlimb muscle ECs 7 days after HLI. Data of Aged + PBS group in G was set as 1. Unpaired two-tail t -test, n = 3 per group, data are mean ± SEM, ∗∗ P < 0.001, ∗∗∗ P < 0.001. (I) Immunofluorescence staining for CD31, α-SMA and KI67 in ischemic adductor muscles 7 days after HLI is shown. Scale bar, 200 μm. (J) Quantification of the percent of KI67 + arterial ECs in total arterial ECs in muscle. Unpaired two-tail t -test, n = 6 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001. (K) Immunofluorescence staining for CD31 and KI67 in ischemic gastrocnemius muscles 7 days after HLI is shown. Scale bar, 200 μm. (L) Quantification of the percent of KI67 + CD31 + cells in total capillary ECs in muscle. Unpaired two-tail t -test, n = 6 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001. (M) Immunofluorescence staining for CD31, α-SMA and γ-H2AX in ischemic adductor muscles 7 days after HLI is shown. Scale bar, 100 μm. (N) Quantification of the percent of γ-H2AX + arterial ECs in arterial ECs in muscle. Unpaired two-tail t -test, n = 6 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001. (O) Immunofluorescence staining for CD31 and γ-H2AX in ischemic gastrocnemius muscles 7 days after HLI is shown. Scale bar, 100 μm. (P) Quantification of the percent of γ-H2AX + CD31 + cells in total capillary ECs in muscle. Unpaired two-tail t -test, n = 6 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001. (Q and R) Representative laser Doppler images of hindlimbs of mice and quantification of relative perfusion recovery as the blood flow ratio of the left limb to that of the right limb in Aged + PBS and Aged + IDO1 mice before and after HLI at the indicated time points. The areas under the curves of relative perfusion are shown, Two-way ANOVA with Tukey multiple comparison test, n = 6 per group, data are mean ± SEM, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗∗ P < 0.0001. (S) Representative micro-CT images of ischemic hindlimbs 21 days after HLI. Scale bar, 3 mm. (T) Quantification of micro-CT analysis of arterial vasculature in ischemic hindlimbs. Two-way ANOVA with Tukey multiple comparison test, n = 6 per group, data are mean ± SEM, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (U) Representative whole-mounted images of ischemic gracilis 21 days after HLI. (V) Quantification of the diameter of pre-existed collateral arteries (6 points per artery). Unpaired two-tail t -test, n = 6 per group, data are mean ± SEM, ∗∗ P < 0.01. (W) Immunofluorescence staining for CD31 in ischemic gastrocnemius muscles 21 days after HLI is shown. Scale bar, 200 μm. (X) Quantification of the CD31-positive area in muscle. Unpaired two-tail t -test, n = 6 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001.

    Journal: Redox Biology

    Article Title: IDO1 improves postischemic neovascularization in aged mice by boosting endothelial NAD + de novo synthesis and curbing endothelial senescence

    doi: 10.1016/j.redox.2025.103695

    Figure Lengend Snippet: IDO1 protein enhances the neovascularization in aged mice following lower limb ischemia. (A) Scheme illustrating the experiment of aged mice administrated with IDO1 protein. (B) Mass spectrometry analysis of NAD + related metabolites in hindlimb muscle ECs 7 days after HLI. Aged + PBS group was set as 1. Two-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗ P < 0.05, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (C) Western blot analysis and quantification of P16 in hindlimb muscle ECs 7 days after HLI. Aged + PBS group was set as 1. Unpaired two-tail t -test, n = 3 per group, data are mean ± SEM, ∗∗∗ P < 0.001. (D–F) RT-qPCR quantification of p16 (D), p21 (E), Lmnb1 (F) in hindlimb muscle ECs 7 days after HLI. Aged + PBS group was set as 1. Unpaired two-tail t -test, n = 3 per group, data are mean ± SEM, ∗ P < 0.05, ∗∗ P < 0.01. (G and H) ROS (G) and NO (H) levels quantification in hindlimb muscle ECs 7 days after HLI. Data of Aged + PBS group in G was set as 1. Unpaired two-tail t -test, n = 3 per group, data are mean ± SEM, ∗∗ P < 0.001, ∗∗∗ P < 0.001. (I) Immunofluorescence staining for CD31, α-SMA and KI67 in ischemic adductor muscles 7 days after HLI is shown. Scale bar, 200 μm. (J) Quantification of the percent of KI67 + arterial ECs in total arterial ECs in muscle. Unpaired two-tail t -test, n = 6 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001. (K) Immunofluorescence staining for CD31 and KI67 in ischemic gastrocnemius muscles 7 days after HLI is shown. Scale bar, 200 μm. (L) Quantification of the percent of KI67 + CD31 + cells in total capillary ECs in muscle. Unpaired two-tail t -test, n = 6 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001. (M) Immunofluorescence staining for CD31, α-SMA and γ-H2AX in ischemic adductor muscles 7 days after HLI is shown. Scale bar, 100 μm. (N) Quantification of the percent of γ-H2AX + arterial ECs in arterial ECs in muscle. Unpaired two-tail t -test, n = 6 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001. (O) Immunofluorescence staining for CD31 and γ-H2AX in ischemic gastrocnemius muscles 7 days after HLI is shown. Scale bar, 100 μm. (P) Quantification of the percent of γ-H2AX + CD31 + cells in total capillary ECs in muscle. Unpaired two-tail t -test, n = 6 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001. (Q and R) Representative laser Doppler images of hindlimbs of mice and quantification of relative perfusion recovery as the blood flow ratio of the left limb to that of the right limb in Aged + PBS and Aged + IDO1 mice before and after HLI at the indicated time points. The areas under the curves of relative perfusion are shown, Two-way ANOVA with Tukey multiple comparison test, n = 6 per group, data are mean ± SEM, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗∗ P < 0.0001. (S) Representative micro-CT images of ischemic hindlimbs 21 days after HLI. Scale bar, 3 mm. (T) Quantification of micro-CT analysis of arterial vasculature in ischemic hindlimbs. Two-way ANOVA with Tukey multiple comparison test, n = 6 per group, data are mean ± SEM, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (U) Representative whole-mounted images of ischemic gracilis 21 days after HLI. (V) Quantification of the diameter of pre-existed collateral arteries (6 points per artery). Unpaired two-tail t -test, n = 6 per group, data are mean ± SEM, ∗∗ P < 0.01. (W) Immunofluorescence staining for CD31 in ischemic gastrocnemius muscles 21 days after HLI is shown. Scale bar, 200 μm. (X) Quantification of the CD31-positive area in muscle. Unpaired two-tail t -test, n = 6 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001.

    Article Snippet: Mouse IL-17A protein (Catalog #HY- P70753 ), mouse IL-17F protein (Catalog #HY- P72584 ), mouse IL-17A/F protein (Catalog #HY- P77707 ), mouse IDO1 protein (Catalog #HY- P72616 ), IgG (Catalog #HY-P99002), brodalumab (Catalog #HY-P9925, an anti-interleukin-17-receptor IgG2 monoclonal antibody), and 666–15 (Catalog #HY-101120, CREB phosphorylation inhibitor) were purchased from Med-ChemExpress.

    Techniques: Mass Spectrometry, Comparison, Western Blot, Quantitative RT-PCR, Immunofluorescence, Staining, Muscles, Micro-CT

    Plasma IDO1 levels are lower in elderly PAD patients and correlate with PAD severity, onset risk, and cardiovascular outcome. ( A ) Schematic diagram for the process of sample collection and correlation analysis between plasma IDO1 levels and clinical indicators. ( B ) ELISA analysis of IDO1 levels in plasma from young and aged mic at 7 days following HLI. Unpaired two-tail t -test, n = 6 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001. ( C ) ELISA analysis of IDO1 levels in plasma from young <65 years: and elderly ≥65 years: patients with PAD. Unpaired two-tail t -test, n = 30 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001. ( D – K ) Spearman correlation between plasma concentration of IDO1 and ABI ( D ), HDL ( E ), PCSK9 ( F ), NLR ( G ), hs-CRP ( H ), Fibrinogen ( I ), D-dimer ( J ) and NT-proBNP ( K ). n = 30 per group. ( L ) Schematic diagram for the changes in plasma IDO1 levels and clinical indicators between young and elderly PAD patients.

    Journal: Redox Biology

    Article Title: IDO1 improves postischemic neovascularization in aged mice by boosting endothelial NAD + de novo synthesis and curbing endothelial senescence

    doi: 10.1016/j.redox.2025.103695

    Figure Lengend Snippet: Plasma IDO1 levels are lower in elderly PAD patients and correlate with PAD severity, onset risk, and cardiovascular outcome. ( A ) Schematic diagram for the process of sample collection and correlation analysis between plasma IDO1 levels and clinical indicators. ( B ) ELISA analysis of IDO1 levels in plasma from young and aged mic at 7 days following HLI. Unpaired two-tail t -test, n = 6 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001. ( C ) ELISA analysis of IDO1 levels in plasma from young <65 years: and elderly ≥65 years: patients with PAD. Unpaired two-tail t -test, n = 30 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001. ( D – K ) Spearman correlation between plasma concentration of IDO1 and ABI ( D ), HDL ( E ), PCSK9 ( F ), NLR ( G ), hs-CRP ( H ), Fibrinogen ( I ), D-dimer ( J ) and NT-proBNP ( K ). n = 30 per group. ( L ) Schematic diagram for the changes in plasma IDO1 levels and clinical indicators between young and elderly PAD patients.

    Article Snippet: Mouse IL-17A protein (Catalog #HY- P70753 ), mouse IL-17F protein (Catalog #HY- P72584 ), mouse IL-17A/F protein (Catalog #HY- P77707 ), mouse IDO1 protein (Catalog #HY- P72616 ), IgG (Catalog #HY-P99002), brodalumab (Catalog #HY-P9925, an anti-interleukin-17-receptor IgG2 monoclonal antibody), and 666–15 (Catalog #HY-101120, CREB phosphorylation inhibitor) were purchased from Med-ChemExpress.

    Techniques: Clinical Proteomics, Enzyme-linked Immunosorbent Assay, Concentration Assay

    FIGURE 2 | UB treatment ameliorates depression-like behaviors and neuroinflammation and abnormal expression of SIRT1 and FOXO1 in the hippocampus of LPS-exposed mice. (A) Scheme of the experimental procedure. (B) SPT, FST, and locomotor tests. (C) Relative mRNA levels of TNF-ɑ, IL-1ɑ, IL-1β, IL-6, and IDO in the hippocampus. mRNA levels of M1 type markers iNOS and CD86 (D), and M2 type markers ARG1 and CD206 (E) in the hippocampus. (F and G) Western blot was performed to evaluate the effect of UB on the protein levels of Iba1, IDO, SIRT1, and FOXO1 in the hippocampus. n = 6–7 per group. #p < 0.05, ##p < 0.01, ###p < 0.001 versus the Vehicle + Vehicle group or LPS + Vehicle group.

    Journal: CNS neuroscience & therapeutics

    Article Title: Alleviation of Microglia Mediating Hippocampal Neuron Impairments and Depression-Related Behaviors by Urolithin B via the SIRT1-FOXO1 Pathway.

    doi: 10.1111/cns.70379

    Figure Lengend Snippet: FIGURE 2 | UB treatment ameliorates depression-like behaviors and neuroinflammation and abnormal expression of SIRT1 and FOXO1 in the hippocampus of LPS-exposed mice. (A) Scheme of the experimental procedure. (B) SPT, FST, and locomotor tests. (C) Relative mRNA levels of TNF-ɑ, IL-1ɑ, IL-1β, IL-6, and IDO in the hippocampus. mRNA levels of M1 type markers iNOS and CD86 (D), and M2 type markers ARG1 and CD206 (E) in the hippocampus. (F and G) Western blot was performed to evaluate the effect of UB on the protein levels of Iba1, IDO, SIRT1, and FOXO1 in the hippocampus. n = 6–7 per group. #p < 0.05, ##p < 0.01, ###p < 0.001 versus the Vehicle + Vehicle group or LPS + Vehicle group.

    Article Snippet: The primary antibodies employed in this study were as follows: rabbit anti- SIRT1 (Sigma- Aldrich, 07- 131), rabbit anti- FOXO1 (CST, 2880S), mouse anti- β- actin (CST, 3700S), rabbit anti- P65 (CST, 8242T), rabbit anti- phospho- P65 (CST, 3031S), ARG1 (BOSTER, A01106), CD206 (BOSTER, A02285- 2), CD86 (BOSTER, A00220- 4), iNOS (BOSTER, BA0362), ERK (CST, 4695), p- ERK (CST, 4370), rabbit anti- P38 (CST, 9212S), phospho- P38 (CST, 9215), JNK (CST, 9251), phospho- JNK (CST, 9252), rabbit anti- AMPK (CST, 5831S), rabbit anti- phospho- AMPK (CST, 2535S), rabbit anti- Bax (CST, 5023T), mouse anti- Bcl- 2 (CST, 15071T), mouse anti- IDO (Proteintech, 66528- 1- Ig), rabbit anti- Ac- FOXO1 (Invitrogen, PA5- 104560), rabbit anti- Ac- P65 (Abcam, AB19870).

    Techniques: Expressing, Western Blot